Stock Analysis of NewAmsterdam Pharma Co. NV (NAMS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code NAMS
Close 18.75
Change 0.230 / 1.24 %
Volume 547724
Vol Change 454821 / 489.57 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of NewAmsterdam Pharma Co. NV
PE (TTM)

-15.43

Very Poor
Price / Book

10.90

Very Poor
Price / Sales

133.91

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

1687.23 M

Enterprise Value

1346.84 M

ROA (TTM)

-58.98

Very Poor
ROE (TTM)

-70.67

Very Poor
Net Margin (TTM)

-867.96

Very Poor
Revenue

85.55 %

14090.00 K
Net Profit

126.69 %

-176937.00 K
Debt to Equity

0.0002

Excellent
Altman Z Score

15.40

Excellent
Quick Ratio

6.99

Excellent
Cash Ratio

6.82

Excellent


Highs/Lows of NewAmsterdam Pharma Co. NV
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week18.82 0.372 % 0.513 % 19.7918.1529-May-2431-May-24
Two Week20.09 6.67 % 0.486 % 20.3518.1520-May-2431-May-24
One Month21.81 14.03 % 4.80 % 23.0118.1502-May-2431-May-24
Three Month22.84 17.91 % 3.56 % 24.7918.1501-Apr-2431-May-24
Six Months9.76 92.11 % 15.54 % 26.29268.925-Jan-2408-Dec-23
One year13.86 35.28 % 26.26 % 26.29265.632625-Jan-2426-Oct-23
Two year9.86 90.16 % 27.72 % 32.885.632623-Nov-2226-Oct-23


Technical View of NewAmsterdam Pharma Co. NV
RSI

37.22

Neutral
MACD

-0.639

Bearish
ADX

26.74

Bearish
Super Trend

22.25

Mild Bearish
Williams %R

-85.29

Mild Bullish
CCI

-98.94

Mild Bullish


EMA 5

18.91

Mild Bearish
EMA 15

19.60

Mild Bearish
EMA 50

20.32

Strong Bearish
EMA 100

19.32

Whipsaw
SMA 100

20.79

Mild Bearish
SMA 200

15.22

Bullish
SMA 5 / 20

18.90 / 20.21

Mild Bearish
SMA 15 / 50

19.64 / 20.77

Bearish
SMA 50 / 200

20.77 / 15.22

Bullish




Charts of NewAmsterdam Pharma Co. NV


Returns of NewAmsterdam Pharma Co. NV with Peers
Period / StockNAMSNEOKROSHRMY
1 Week-0.372%-3.72%-3.32%-1.84%
1 Mth-14.03%-1.51%-16.88%-4.89%
3 Mth-17.91%-12.12%-30.56%-8.41%
6mth92.11%-24.55%54.48%1.17%
1 Year35.28%-20.20%-2.07%-14.98%
2 Year90.16%62.83%38.67%-32.57%
5 Years--36.85%--
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of NewAmsterdam Pharma Co. NV with Peers
Ratio / StockNAMSNEOKROSHRMY
PE-15.43-20.47-2175.2912.70
P/B10.901.82988.813.65
ROA-58.98-5.01-41.6817.60
ROE-70.67-8.88-45.4628.78
Debt To Equity0.00020.5780.00300.414
Revenue14090.00 K
85.55 % 		591643 K
16.07 % 		151000
99.25 % 		541918 K
23.77 %
Net Income-176937.00 K
126.69 % 		-87968.00 K
39.02 % 		-152992.00 K
46.15 % 		150755 K
16.92 %


Technicals of NewAmsterdam Pharma Co. NV with Peers
Technical / StockNAMSNEOKROSHRMY-
ADX26.7416.2239.0611.82
CMF-0.211-0.0497-0.181-0.132
MFI34.3130.866.2043.97
RSI37.2239.0429.8445.98
MACD Abv SignalFalseFalseFalseFalse
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MATrueFalseTrueFalse-


About : NewAmsterdam Pharma Company N.V.

Address : Gooimeer 2-35, Naarden, Netherlands, 1411 DC
Tel : 31 35 206 2971
URL : https://www.newamsterdampharma.com
Code : NAMS, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 23_Nov_2022
Employee Count : 40

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.


Note : All Data Generated at the End of Trading Hours (EOD Data)